All In Biotech

Drug Trial Radar · NCT03708354

Tocotrienols for Skeletal Muscle Health

Tocotrienols Supplementation for Postmenopausal Women With Low Muscle Strength

Last checked: Nov 19, 2026Latest source record: Feb 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Apr 15, 2019

Primary completion

Dec 31, 2022

Study completion Dec 31, 2022

Sponsor

Lead sponsor
Texas Tech University Health Sciences CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 60 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Sarcopenia, defined as a reduction in muscle mass and strength, is a major health concern for postmenopausal women. Evidence suggests that lowering inflammation levels is an important strategy to help mitigate age-related muscle dysfunction and loss. In this pilot study, the investigators will study a tocotrienol (vitamin-E isomer) intervention for feasibility and quantify its effects on postmenopausal women with low muscle strength. A double blind, placebo controlled trial will be conducted on fifty-two qualified subjects. The participants will be assigned to placebo or tocotrienols for 24 weeks. All participants will receive an Omron Alvita Optimized Pedometer. The investigators will measure muscular endurance, strength, and size and gut microbiome profiles at 0, 12, and 24 weeks. In addition, the investigators will measure serum and muscle inflammatory levels at 0 and 24 weeks. All data will be analyzed statistically at p\<0.05.

Conditions

  • Dynapenia
  • Postmenopausal Women

Interventions

  • placebo softgelDrug

    One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.

  • DeltaGold® Tocotrienol 70%Drug

    Each TT softgel (DeltaGold® Tocotrienol 70%) contains 430 mg TT (90% δ-TT+10% γ-TT) with a 70% purity, representing 300 mg TT.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. lower-body muscle enduranceTime frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Texas Tech University Health Sciences Center

    Lubbock, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.